Точка Синхронізації

CSL Limited Chief Executive Officer Paul McKenzie reported a significant 81% decline in net profit after tax during the company’s first-half 2026 earnings call held at the corporate headquarters in Melbourne on February 11, 2026, citing a series of one-off strategic restructuring costs and high-interest expenses. The Australian biotech giant’s financial performance was heavily impacted by the deliberate transition of its CSL Vifor business unit and the costs associated with integrating recent acquisitions, which masked a robust underlying growth in its core Behring immunoglobulin portfolio. Despite the sharp drop in statutory profit, the company maintained its revenue guidance, emphasizing that the downturn reflects a temporary transition toward a more streamlined operating model. The decline in profitability was primarily driven by a non-cash impairment of assets related to the Vifor acquisition, a deal originally intended to diversify CSL's portfolio into iron deficiency and nephrology treatments. Investors were also briefed on the rising cost of sales, fueled by lingering inflationary pressures on plasma collection. However, the Behring division showed remarkable resilience, with double-digit growth in its HAEGARDA and Hizentra products, suggesting that the company's fundamental demand remains strong despite the bottom-line volatility seen in the first half of the fiscal year. Looking ahead, management outlined a strategic shift toward 'yield-per-liter' optimization to improve margins in the plasma business, alongside a refined focus on the late-stage R&D pipeline. The company is betting on its new self-amplifying mRNA (sa-mRNA) vaccine technology to drive future growth in its CSL Seqirus division, which faced a challenging flu season. Financial analysts noted that while the 81% profit drop appeared alarming on paper, the underlying cash flow and consistent dividend payout signaled a degree of confidence from the board regarding the long-term success of the current structural overhaul.